
The BioHub - by Avetix Episode 111 - Kevin Pojasek - President and CEO of Enara Bio
Feb 3, 2026
34:21
We were delighted to be joined by Kevin Pojasek who's the President and CEO of Enara Bio.
Enara Bio is shining a light on Dark Antigen and T-cell biology to develop cancer immunotherapies designed to improve treatment outcomes for broad populations of cancer patients with solid tumors. There pioneering EDAPT® platform enables us to discover cancer-specific antigens from previously uncharted genomic ‘dark matter’. The result is a growing library of Dark Antigens that can address the need for novel, cancer-specific targets in solid tumors.
In this we cover:
- The spark that led to the founding of Enara Bio
- Enara's platform EDAPT® and how it finds dark antigens in tumors.
- Where the field of T-Cell therapy for solid tumors is today.
- The importance of culture in early stage biotech, and how the company has been built around putting people first.
- The next major milestones for Enara Bio.
